Wedbush Forecasts Perspective Therapeutics FY2025 Earnings

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Stock analysts at Wedbush increased their FY2025 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research note issued to investors on Tuesday, November 11th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($1.33) for the year, up from their previous estimate of ($1.34). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics’ Q4 2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($1.27) EPS.

Other research analysts have also issued research reports about the stock. BTIG Research started coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.89.

Perspective Therapeutics Trading Down 4.0%

CATX stock traded down $0.09 during trading hours on Thursday, hitting $2.04. 167,000 shares of the stock traded hands, compared to its average volume of 1,008,623. The company has a current ratio of 15.09, a quick ratio of 15.09 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $3.30 and a 200 day simple moving average of $3.32. Perspective Therapeutics has a one year low of $1.60 and a one year high of $10.06.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CATX. Russell Investments Group Ltd. boosted its position in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the period. SG Americas Securities LLC acquired a new position in Perspective Therapeutics during the 3rd quarter valued at $46,000. Ground Swell Capital LLC acquired a new position in Perspective Therapeutics during the 2nd quarter valued at $56,000. Los Angeles Capital Management LLC bought a new stake in Perspective Therapeutics in the 2nd quarter valued at $61,000. Finally, MetLife Investment Management LLC grew its position in Perspective Therapeutics by 40.9% in the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock worth $67,000 after purchasing an additional 9,082 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.